International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationChanges in Cervical Cancer FDG Uptake During Chemoradiation and Association With Response
Introduction
Approximately 20%-40% of patients with locally advanced cervical cancer treated with definitive chemoradiation will have persistent or recurrent disease after treatment 1, 2. Being able to identify those patients at high risk for a poor response to conventional therapy before or during treatment could lead to improved outcomes through modification of the treatment plan or use of adjuvant therapy.
Previous studies identified 3 different positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET)-based prognostic factors for intact cervical cancer being treated definitively with concurrent chemoradiation. Specifically, high FDG uptake in the primary cervical tumor, measured as the maximum standardized uptake value (SUVmax) predicted for lymph node involvement, treatment response, recurrence risk, and overall survival (3). Similarly, the degree of variability of FDG uptake (FDGhetero) across a primary cervical tumor predicted for lymph node involvement, treatment response, local recurrence, and progression-free survival (4). Earlier research also found that primary cervical metabolic tumor volume (MTV) assessed on FDG-PET is associated with progression-free and overall survival (5).
Based on these studies, a prospective pilot study was initiated to evaluate how SUVmax, FDGhetero, and MTV changed during chemoradiation, using week 2 and week 4 during-treatment PET, and analyzing how these changes correlated with response on 3-month post-therapy PET, as other research showed that response assessment at this time predicted long-term outcome and survival (6).
Section snippets
Patients
This prospective cohort study included 25 patients with newly diagnosed International Federation of Obstetrics and Gynecology stage Ib1-IVa cervical cancer who were treated definitively with concurrent cisplatin and radiation. The study was approved by the Human Research Protection Office (HRPO 08-0804). Written informed consent was obtained from all patients.
All patients were treated with a combination of external beam radiation therapy (EBRT), high-dose-rate (HDR) intracavitary brachytherapy,
Patient characteristics
Twenty-five patients enrolled on the study between September 2008 and October 2010. Initial patient characteristics are included in Table 1. The average pretreatment PET characteristics were: primary cervix tumor SUVmax was 17.8 (range, 6.2-32.3), FDGhetero was −1.33 (range, −6.2 to −0.16), and MTV 55.4 cm3 (range, 7.6-251.1 cm3).
During-treatment FDG-PET changes
Figure 1 shows examples of the changes in primary cervical tumor FDG uptake during the course of therapy; qualitatively, we noted that the areas of highest FDG uptake
Discussion
Performing FDG-PET during treatment offers a unique opportunity to assess response to therapy before the completion of treatment, which could allow for modifications to improve the long-term outcome for patients. During-treatment imaging was initially applied for chemotherapy treatment assessment 7, 8. More recently, various groups have assessed during-treatment PET response with radiation or chemoradiation for cancers of the lung, rectum, and other sites 9, 10, 11, 12, 13, 14. Although
Conclusion
With 20%-40% of cervical cancer patients treated with concurrent chemoradiation experiencing recurrent or persistent disease 1, 2, being able to identify these high-risk patients in order to provide treatment intensification could have significant benefits. The present study confirms the prognostic value of pretreatment PET-based factors and identifies week 4 of treatment as another valuable time point for providing an early assessment of response, specifically with week 4 SUVmax and FDGhetero
References (20)
- et al.
Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy
Int J Radiat Oncol Biol Phys
(2002) - et al.
Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients
Radiother Oncol
(2007) - et al.
Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study
Int J Radiat Oncol Biol Phys
(2008) - et al.
Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer
Radiother Oncol
(2011) - et al.
FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer
Int J Radiat Oncol Biol Phys
(2006) - et al.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
Eur J Cancer
(1999) - et al.
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group
Eur J Cancer
(1995) - et al.
18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging
Int J Radiat Oncol Biol Phys
(2010) - et al.
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01
J Clin Oncol
(2004)
Cited by (0)
Conflict of interest: none.
Funding provided by RO1 CA136931 and 2008 RSNA Resident Research Grant #RR00807.